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THE HUMAN GUT MICROBIOME AND THE FUTURE ROLE OF FECAL  
MICROBIOTA TRANSPLANTS 
DANIEL DWYER 
ABSTRACT 
 With recent research being conducted in categorizing and analyzing the 
human microbiome, evidence has now linked the human microbiome to a range 
of diseases. Dysbiosis of the human gut microbiome exists in colon cancer, 
obesity, and Clostridium difficile infections. The use of fecal microbiota 
transplants has been proven effective in treating recurrent C.difficile infections by 
restoring gut microbiota. More needs to be done to establish fecal microbiota 
transplants procedures, effectiveness, and safety. Once established, fecal 
microbiota transplants may play a role in modulating other diseases linked to 
human gut microbiome dysbiosis. 
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INTRODUCTION 
 Around ten trillion microbial cells live inside a human being’s gut (Mullard, 
2008). This equates to ten times as many foreign cells than human cells 
(National Institute of Health, 2014). These microbial inhabitants, referred to as 
the human microbiome, harbor more than 100 times as many genes than the 
entirety of the human genome (Mullard, 2008). Back in 2005, an international 
conference was convened to discuss an effort to categorize the community of 
microbes in the human gut, as well as other epithelial linings, such as the skin, 
vagina, and oral mucosa (The NIH HMP Working Group et al., 2009). Shortly 
after, in 2008 the National Institute of Health (NIH) created the Common Fund 
Human Microbiome Project (HMP) with the mission of categorizing and analyzing 
the human microbiome in order to resolve the role it plays in human health and 
disease (National Institute of Health, 2014). HMP was designed to fund this 
cutting edge research. Similarly to the HMP, European MetaHIT consortium used 
the same techniques to investigate only the human gut microbiome (Arumugam 
et al., 2011). 
 The Human Microbiome Project has been planned out to conquer four 
different challenges of sampling and analyzing the HMB: analyzing 16S rRNA 
gene diversity in order to characterize the complex communities, using whole 
genome shotgun approach to analyze what genes are present and potentially 
active, isolating and mapping genomes in order to build a reference database, 
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and to then investigate the potential relationships between human microbiota and 
disease (Aagaard & Segars, 2014; The NIH HMP Working Group et al., 2009).  
1.1 Analyzing 16S rRNA Genes 
Recent advances in technology have allowed researchers to define and 
categorize bacterial species commonly found inhabiting in and on humans 
(Weng, Rubin, & Bristow, 2006). This commensal relationship is referred to as 
the human microbiome. Previous attempts at quantifying and analyzing the 
microbiome were foiled by the inability to culture all species that inhabited 
various locations of the human (Connon & Giovannoni, 2002; Pei et al., 2004; 
Verhelst et al., 2004) . In fact, culture based methods failed to identify up to 80% 
of organisms because of the organisms inability to grow in culture (Connon & 
Giovannoni, 2002; Hugenholtz, 2002; Pei et al., 2004; Verhelst et al., 2004; 
Weng et al., 2006). Because of this limitation, previous bacterial analyses have 
mostly investigated proverbial bacterial “weeds” that easily grow on culture 
medium (Hugenholtz, 2002). 
The use of ribosomal RNA gene sequencing has allowed culture-
independent identification of bacteria since these genes are sufficiently 
conserved across species, allowing PCR amplification, but variable enough to 
distinguish between different bacterial species (Weng et al., 2006). The most 
commonly used conserved sequence is the 16S rRNA gene (Hugenholtz, 2002; 
Mills, Entry, Voss, Gillevet, & Mathee, 2006; National Institute of Health, 2014). 
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By using PCR amplification or RNA cloning, one is able to bypass the need to 
culture a bacterial species before analysis as seen in Figure 1. The use of whole-
cell fluorescence in situ can then be used to visualize and quantify the amounts 
of specific bacteria in a specific sample (Hugenholtz, 2002). In addition, recent 
developments have reduced the cost and sped up these processes so that 
analyzing the multitude of genes, which are in the order of millions, is no longer 
impossibly difficult (Mullard, 2008). 
Figure 1. PCR and Cloning Eliminate Need for Culture 
Nucleic acid probes are generated from existing databases of 16S rRNA genes. They are then 
applied to RNA/DNA samples extracted from environmental samples. Either PCR or Cloning is 
utilized to generate sufficient substrate for detection and sequencing of the sample (Hugenholtz, 
2002) 
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 Researchers have purified and analyzed over 3.5 terabases of genomic 
data to be able to quantify and categorize bacteria (“NIH Human Microbiome 
Project defines normal bacterial makeup of the body,” 2013). In addition, by using 
16S rRNA, researchers have been largely able to ignore human DNA sequences 
since the 16S rRNA sequences are primarily found in bacterial cells (The NIH 
HMP Working Group et al., 2009). Furthermore, new techniques for analyzing 
and obtaining this 16S rRNA data are ever improving the reliability and accuracy 
of their measurements (Schloss, Gevers, & Westcott, 2011) 
1.2 Whole Genome Shotgun Approach 
In addition to classifying specific bacterial populations through 16S rRNA, 
another focus is on identifying the various roles the bacterial genomes play in 
metabolite processing (Methe et al., 2012). While 16S rRNA can tell researchers 
what species of bacteria are present, they do little to identify the function of those 
bacterial species (Methe et al., 2012). Whole genome shotgun (WGS) techniques 
take the whole communities DNA into account (Methe et al., 2012; The NIH HMP 
Working Group et al., 2009). This approach is called “Metagenomics”, which 
sequences genomic libraries directly from a mixed sample (The NIH HMP 
Working Group et al., 2009). 
 The human genome only carries around 22,000 protein-coding genes; 
however, the microbiome inhabiting humans contribute around 8 million unique 
protein coding genes (“NIH Human Microbiome Project defines normal bacterial 
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makeup of the body,” 2013). That means that the microbes have the potential to 
contribute around 360 times more proteins towards the survival of the human 
host than the human host itself. Because of this, it is essential to investigate not 
only what species of microbe exist, but also what they do. For example, microbial 
genes in the human gastro-intestinal tract are responsible for digesting certain 
foods and nutrients for the human host that would otherwise be unavailable (“NIH 
Human Microbiome Project defines normal bacterial makeup of the body,” 2013). 
1.3 Reference Database 
Through the use of a variety of methods, including sample dilution, 
micromanipulators, optical tweezers, filtration, centrifugation, and flow cytometry, 
hard to grow bacteria have been isolated and analyzed (Elsas, 1997). These 
methods have laid the groundwork in developing a database of genes used to 
classify and investigate the human microbiome. 
In order to gain an insight into what a “normal” western microbiome 
constitutes, the HMP obtained samples from 242 volunteers from two distinct 
geographical locations in the United States, meeting an extensive list of inclusion 
and exclusion criteria defining “normal” from the United States of America; 
samples were taken from 15 body sites on both males and females (Figure 2), 
with an additional 3 sites for the female reproductive tract (The Human 
Microbiome Project Consortium, 2012). Gastrointestinal bacteria were analyzed 
using stool samples (The NIH HMP Working Group et al., 2009). Replicate 
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measures were taken 1 month to over a year after initial sampling. All samples 
were analyzed using 16s rRNA sampling, with a subset also analyzed using 
whole shotgun genome approaches. 
Figure 2. HMP Sample sites 
Multiple sites were sampled and analyzed (“Human Microbiome Project DACC - Microbiome 
Analyses,” 2014). 
In addition, subjects were sampled up to two more times in the following 
months (The NIH HMP Working Group et al., 2009). Following the flow in Figure 
3, the samples were analyzed and to increase the reference genome database 
(The NIH HMP Working Group et al., 2009). As of 2/1/2014, the human 
microbiome project (HMP) has 2673 reference genome projects in the works, 
spanning many human sample sites (“Human Microbiome Project DACC - HMP 
Project Catalog,” 2014). Of these 2673 projects, there are over 1300 reference 
microbial genomes that have already been completed (“Human Microbiome 
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Project DACC - HMRGD,” 2014). That’s over 1.84 Terabytes of information that 
has been analyzed by the scientific community (“Human Microbiome Project 
(HMP) Metagenome Projects (ID 43017) - BioProject - NCBI,” 2014). Reference 
genes can be obtained from both the National Center for Biotechnology 
Information’s website NCBI.gov and the Human Microbiome Project’s website 
HMPDacc.org. 
Figure 3. HMP Sample Analysis Pathway Flowchart 
This flow chart represents the path the HMP has taken to analyze and sort subject samples into 
useful reference genomic material. Microbial communities are analyzed by both WGS and 16S 
rRNA methods to produce respective reference data. (The NIH HMP Working Group et al., 2009) 
1.4 What Constitutes “Normal” 
 The work of many investigators and extensive analysis has laid the 
groundwork in establishing what is considered a “normal” microbiome (The 
Human Microbiome Project Consortium, 2012). These microbial communities 
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have been analyzed using reference genomic material obtained through the HMP 
(The Human Microbiome Project Consortium, 2012).  
 It was determined that the difference in microbial community makeup was 
highly variable when looking at a single subject across sampling sites, as in the 
bacterial composition varied vastly from skin to vaginal to oral to gastrointestinal 
sampling sites (The Human Microbiome Project Consortium, 2012). However, the 
difference between subjects when looking at the same sampling site was 
markedly less, with salvia having the highest diversity within a sample, but as a 
population shared a similar organism makeup (The Human Microbiome Project 
Consortium, 2012). Thus, an individual subject’s saliva has a wide variety of 
organisms but is markedly similar to the saliva from another subject. The vagina 
had the lowest microbial diversity when looking at a single subject, as well as 
when comparing between subjects at the genus level; however, the bacterial 
composition between subjects had a very high diversity among operational 
taxonomic units (OTUs, approximately classify species, see 
http://hmpdacc.org/HMQCP) due to the presence of distinct lactobacillus species 
(The Human Microbiome Project Consortium, 2012). The diversity seen in 
microbial species could be roughly sorted into one of five groups: 
gastrointestinal, urogenital, nasal, oral, and skin samples (Figure 4). It has also 
been discovered that there is usually a predominant phyla in each of 
the sampling sites (Figure 5), and there is no universal microbe found across all 
body habitats (The Human Microbiome Project Consortium, 2012). 
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Figure 4. Diversity of Human Biome Roughly Grouped by Region 
Principal coordinate plot showing the primary variation in the human microbiome is clustered by 
body regions. Nasal regions straddle skin and oral habitats. (The Human Microbiome Project 
Consortium, 2012) 
Current distribution of genes surprised scientists in that the distribution of 
metabolic activities was more important than the distribution of microbial species 
(“NIH Human Microbiome Project defines normal bacterial makeup of the body,” 
2013). As shown in Figure 5, metabolic pathways are relatively stable across 
individuals when examining a single habitat. This is exemplified in stool where 
there is a high variability among phyla dominance with an inverse relationship 
between Bacteroidetes and Firmicutes (Figure 6) as the competing dominate 
phyla in stool, yet a relatively stable metabolic profile still emerged (The Human 
Microbiome Project Consortium, 2012). 
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Figure 5. Phlya Distribution Varies Across Select Sampling Sites and Subjects 
Relative average abundance of different phyla across subjects and their sample sites are shown 
by vertical bars. One phyla usually predominates the site, but this is not absolute (The Human 
Microbiome Project Consortium, 2012).  
 
 
Figure 6. Metabolic Pathways Remain Consistent Across Subjects 
Vertical bars represent varying average abundance of the most prevalent metabolic pathways 
across subjects and sampling sites. Metabolic pathways are much more stable across subjects 
than phyla (The Human Microbiome Project Consortium, 2012). 
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In addition, unlike the microbial taxa makeup, several metabolic pathways 
were omnipresent, with the most abundant being ribosome and translational 
machinery, nucleotide charging and ATP synthesis, and glycolysis, all of which 
are the fundamentals of host-associated microbe life (The Human Microbiome 
Project Consortium, 2012). Of note, up to 86% of the gut genes detected could 
not be prescribed a metabolic function (Li, Bihan, Yooseph, & Methe, 2012; The 
Human Microbiome Project Consortium, 2012). Low abundant taxa and 
metabolic pathways, while rare, are consistently found in more than 92% of 
samples, which suggest this is an important pool of genetic diversity in the 
human microbiome (Li et al., 2012; The Human Microbiome Project Consortium, 
2012). 
  With repeated sampling taken from the same subjects over time, it was 
discovered that the variation of an individual’s biome was consistently low, in 
both species classification and metabolic functions (The Human Microbiome 
Project Consortium, 2012). Microbial metabolism: remains relatively stable 
among individuals, can change to meet nutrient and metabolite availabilities, and 
vary depending on their environment (Abubucker et al., 2012; The Human 
Microbiome Project Consortium, 2012). There was also high variability 
dependent on subject ethnicity (The Human Microbiome Project Consortium, 
2012). 
It was noted that there was a particular absence of detrimental microbes, 
which supports that a healthy microbiome may be distinctly different than those in 
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disease states (The Human Microbiome Project Consortium, 2012). Data 
continues to suggest that carriage pattern is similar to that of genetic traits, in that 
high-risk detrimental pathogens (like genetic traits) are maintained in the 
population at miniscule to absent levels, whereas those that pose a moderate 
risk are present, but at a low rate (The Human Microbiome Project Consortium, 
2012). 
It was found that twins and their mothers had more similar microbiomes 
than when compared to strangers (Turnbaugh et al., 2009). This suggests that 
the microbiome may be partially inherited by vertical transmission from mother to 
child. Also Bacteroidetes were directly related to functional diversity (Turnbaugh 
et al., 2009). In fact, the microbiome commensally develops with the host, 
supporting the human body, and effecting the host’s wellbeing by protecting the 
host from invasive pathogens as well as helping breakdown indigestible food for 
the host (Y.-T. Tsai, Cheng, & Pan, 2014) 
1.5 Human microbiome implicated in health and disease 
 The HMP and the European metaHIT projects have increased our 
understanding and knowledge of what constitutes normalcy in the human 
microbiome. Now with these reference genes at the public’s disposal, scientists 
are investigating how human health is affected by differing states of the human 
microbiome. 
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1.5.1 Clostridium difficile and the gut microbiome 
The United States Centers for Disease Control and Prevention (CDC) has 
deemed Clostridium difficile infection (CDI) as one of the most significant hospital 
acquired infections (Dynamed, 2013). In fact, CDI causes such severe diarrhea 
that it can be associated with over 14,000 American deaths every year (Centers 
for Disease Control and Prevention, 2013). CDI is a prime example of gut 
bacterial dysbiosis leading to disease (Dynamed, 2013). C. difficile is an 
endospore forming anaerobic gram-positive large rod bacteria which produces 
two toxins that induce foul smelling watery diarrhea in patients (Dynamed, 2013). 
CDI is primarily a hospital-acquired disease in older patient populations in 
hospitals receiving antibiotic treatment (Dynamed, 2013). In about 20% of 
patients, CDI will resolve on its own when discontinuing the antibiotic that the 
patient was previously treated with (Centers for Disease Control and Prevention, 
2013). On the other hand, in 12-20% of patients experiencing their first bout of a 
CDI will be plagued with recurrent CDI, and if this happens, 50-65% of those 
experiencing their second bout will continue to have recurrent episodes of CDI 
(Dynamed, 2013). Unfortunately, current antibiotic treatments are only around 
30% effective at curing this type of recurrent CDI, and the more reoccurrences 
that happen, the less effective antibiotic treatments are (Dynamed, 2013). 
The use of antibiotics can affect both the size and composition of the gut 
microbiome, with some bacterial genera gaining in proportion and others 
shrinking (Britton & Young, 2014). In contrast to patients who did not develop 
 14 
 
CDI after antibiotic treatment, it has been shown that patients who acquire CDI 
after antibiotic use have decreased bacterial diversity, with susceptibility linked to 
a decrease in normal members of the gut microbiome with relative increases in 
others, mainly members of Lachnospiraceae and an increase in 
Enterobacteriaceae (Britton & Young, 2014). Furthermore, those that endured 
recurrent episodes of CDI have distinctly different microbiomes than those who 
did not (Rea et al., 2012). There seems to be a protective effect by 
Lachnospiraceae in mice, which limited the both the severity of symptoms and 
amount of colonization by C. difficile in susceptible mice (Reeves, 
Koenigsknecht, Bergin, & Young, 2012). In fact, 6 phylogenetically diverse 
bacterial species were identified that could restore colonization resistance and 
prevent chronic carriage of C. difficile, when administered together (Lawley et al., 
2012). These studies show that the makeup of an individual’s gut microbiome 
can heavily influence the susceptibility and outcome of a CDI. It has been shown 
that antibiotics affect the gut microbiome, allowing opportunistic infection by C. 
difficile, which can be modulated by various other microbiota (Britton & Young, 
2014; Lawley et al., 2012; Reeves et al., 2012). 
The exact mechanism by which C. difficile overwhelms the native 
microbiome is not entirely known (Dynamed, 2013). However, there have been 
mouse experiments to investigate these mechanisms (Ng et al., 2013; Stiemsma, 
Turvey, & Finlay, 2014). Ng et al. (2013) identified that the use of antibiotics 
reduced host gut bacteria allowing an increase in “free” host carbohydrates. 
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These free carbohydrates were then utilized by the pathogenic C. difficile 
bacteria to establish an infection. However, Ng et al. (2013) continued to show 
that C. difficile infections were also modulated by the composition of the 
underlying microbiota. Gnotobiotic mice with only Bacteroides 
theatatiotaomicron, which contain a sialidase used to free sialic acid from the gut 
mucosa, showed an increased colonization by C. difficile, which can utilize sialic 
acid as an energy source, relative to germ-free mice (Ng et al., 2013); therefore, 
other bacteria may provide beneficial growth conditions for C.difficile. 
Furthermore, Ng et al. (2013) also showed that mutant C. difficile, which lacked 
the genes to utilize sialic acid as a carbon source, resulted in a fourfold decrease 
in colony forming units per gram of feces. Antibiotic usage disrupts the gut 
microbiome, freeing previously consumed nutrients, such as sialic acid, allowing 
the opportunistic C. difficile to utilize this and proliferate into a pathological 
causing infection (Britton & Young, 2014; Ng et al., 2013; Stiemsma et al., 2014).  
Theriot et al. (2014) also showed that the use of antibiotics in mice created 
susceptible states marked by higher concentrations of primary bile acids, 
taurocholate and other tauro-conjugate bile acids, a decrease in secondary bile 
acids such as, deoxycholate, and a marked increase in sugar alcohols, most 
notably mannitol and sorbitol. The increase in free carbohydrates also occurred 
simultaneously with a decrease in free short-,medium- and long-chain fatty acids 
(Theriot et al., 2014). All of these substrates increase C. difficile spore 
germination in in vitro growth studies (Theriot et al., 2014).  
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Colonization resistance to CDI depends on specific microbiome 
community structure and not the overall community size (Theriot et al., 2014). 
Interestingly enough, in experiments with hamsters, it was shown that being 
colonized by nonpathogenic C. difficile conveyed resistance when hamsters were 
subsequently introduced to a pathogenic strain of C. difficile (Merrigan, Sambol, 
Johnson, & Gerding, 2003; Sambol, Merrigan, Tang, Johnson, & Gerding, 2002). 
This parallels previous findings in humans, where earlier non-symptomatic C. 
difficile colonization reduced the chances of developing a CDI (Shim, Johnson, 
Samore, Bliss, & Gerding, 1998). CDI is clearly caused by bacterial dysbiosis. 
New treatments exploring how to treat and perhaps even prevent CDI would be a 
boon to the human population and those currently suffering from the 
uncomfortable and sometimes deadly symptoms of CDI. 
1.5.2 Colon cancer and the gut microbiome 
There are multiple types of cancer that are caused by infectious agents, 
and these malignancies are often in tissues that experience a high level of 
contact with microbes (Zhu, Gao, Wu, & Qin, 2013; zur Hausen, 2009). Well-
known instances include cervical cancer and gastric cancer, often caused by 
human papillomaviruses and the bacteria Helicobacter pylori, respectively (Zhu 
et al., 2013; zur Hausen, 2009). It is interesting to note that there is an 
approximately 12 fold increased risk of cancer of the large intestine (colon), 
which has ~1012 cells/ml, compared to that of the small intestine, which has ~102 
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cells/ml (Proctor, 2011). Considering that there are previous examples of 
infectious agents causing cancer and that the colon is in contact with trillions of 
potentially infectious microbes,  it is no surprise that in recent studies scientists 
are confirming that there is a strong relationship between the gut microbiome and 
colon cancer (Gold JS, Bayar S, & Salem RR, 2004; Moore & Moore, 1995; 
Nakamura et al., 2002; Peek & Blaser, 2002; Zhu et al., 2013).  
Colon cancer is the third most common cancer, but second leading cause 
of mortality in men and women, with over 131,000 incidences and 57,000 deaths 
in 2010 (Centers for Disease Control and Prevention, 2014). Colorectal cancer 
(CRC) is cancer of the large intestine or rectum (Centers for Disease Control and 
Prevention, 2014). Sporadic colorectal cancer (that which cannot be explained by 
inherited genetic deficiencies) normally progresses from healthy gut mucosa to 
an adenoma (benign tumor of the epithelial tissue) and onto carcinoma (Al-
Sohaily, Biankin, Leong, Kohonen-Corish, & Warusavitarne, 2012). Non-inherited 
colorectal cancer is dominated by the chromosomal instability pathway, which 
accounts for 65-70% of all random CRC (Al-Sohaily et al., 2012). This pathway is 
characterized by either entire chromosome loss or partial chromosome loss 
followed by progressive deleterious mutations and cellular damage, following a 
slow but progressive path from healthy mucosa to adenoma to carcinoma (Al-
Sohaily et al., 2012). Due to the slow progression, if caught early, most patients 
will be cured of their cancer (Centers for Disease Control and Prevention, 2014). 
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In previous research, Streptococcus bovis, the genus Bacteroides, the 
class Clostridia, and H. pylori have been implicated in cancer pathogenesis (Gold 
JS et al., 2004; Moore & Moore, 1995; Nakamura et al., 2002; Peek & Blaser, 
2002). On the other hand, some bacterial strains, including Bifidobacterium 
longum and Lactobacillus acidophilus, have been shown to inhibit carcinogen-
induced colon tumor development (McIntosh, Royle, & Playne, 1999; Rowland, 
Bearne, Fischer, & Pool‐Zobel, 1996). These results suggest that the balance 
between “good” and “bad” bacteria may affect the progression of cancer (Zhu et 
al., 2013). 
High concentrations of bacteria were apparent in 90% of biopsy 
specimens from patients with colorectal cancer, with bacteria also apparent in 
93% of samples collected from patients with colonic adenomas, which is in direct 
contrast to finding no bacteria in asymptomatic controls (Swidsinski et al., 1998). 
Furthermore, Escherichia coli strains that were adherent or invasive were present 
in the colonic mucosa of patients with colorectal carcinoma and adenoma, but 
not in normal colonic mucosa (Cuevas-Ramos et al., 2010). S. bovis has been 
linked to colonic neoplasia: this bacterial strain, as well as its bacterial cell wall 
antigens, have been shown to initiate the transformation of normal mucosal 
crypts into hyper-proliferative abnormal colonic crypts and also augment the 
expression of proliferation markers in rats treated with carcinogens (Ellmerich, 
Djouder, Schöller, & Klein, 2000). Taken together, these results suggest that 
bacteria may be directly responsible for some types of CRC. 
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Human colonic dysbiosis in patients with CRC was reported in high-
resolution maps by multiple investigators (Castellarin et al., 2012; W. Chen, Liu, 
Ling, Tong, & Xiang, 2012; Kostic et al., 2012; Marchesi et al., 2011). These 
studies obtained samples from late stage CRC tumors and healthy tissue. Higher 
levels of Fusobacterium spp. were observed in cancerous lesions than matched 
healthy controls (Castellarin et al., 2012; W. Chen et al., 2012; Kostic et al., 
2012). Histological analysis showed that Fusobacterium can invade tumor cells, 
which may explain why a positive correlation was found between Fusobacterium 
and metastases to lymph nodes (Castellarin et al., 2012). In addition to 
Fusobacteriacium, Bacteroidaceae, Peptostreptococcaceae, Streptococcaceae, 
Veillonellaceae, and Pasteurellaceae have been found to be enriched in 
cancerous tissue compared to the intestinal lumen, with Luminococcaceae, 
Lachnospiraceae, and Lactobacillaceae being relatively depleted in cancerous 
tissue compared to the intestinal lumen (W. Chen et al., 2012). When comparing 
bacteria attached to the mucosa of cancerous lesions to matched healthy 
controls, Bifidobacterium, Blautia, and Faecalibacterium were depleted in CRC 
individuals, whereas Porphyromonas, Fusobacterium, Peptostreptococcus, and 
Mogibacterium were increased (W. Chen et al., 2012). On the phylum level in 
patients with CRC, Proteobacteria had higher concentration while Bacteroidetes 
were lower when compared to matched controls (Shen et al., 2010). At the genus 
level CRC patients had increased Dorea spp., Faecalibacterium spp., but had 
 20 
 
fewer Bacteroides spp. than controls (Shen et al., 2010). These results continue 
to support that bacterial dysbiosis is associated with CRC development. 
With these associations one may ask: What if there were no bacteria 
present? Would CRC still develop? In only 20% of germ-free rats did 
carcinogenic chemicals generate CRC, in contrast to 93% of germ-filled rats (Zhu 
et al., 2013). Multiple animal studies have continued to show that having 
microbiota present in the intestine presents a significantly larger CRC risk than 
having a sterile microbiome (Balish & Warner, 2002; Engle et al., 2002; Erdman 
et al., 2003; Gold JS et al., 2004; Kado et al., 2001; Marteau, Vrese, Cellier, & 
Schrezenmeir, 2001; Takaku et al., 1998; Zhu et al., 2013). These data continue 
to support that the gut microbiome plays a crucial part in the development of 
CRC. 
There are multiple possible ways bacteria may influence the development 
of CRC. In addition to the enzymatic conversion of primary bile acids into 
secondary bile salts, increased carcinogen production associated with anaerobic 
bacteria may contribute to the progression of CRC (Owen, 1997). Chronic 
inflammation induced by bacteria, either through innate immune responses to the 
bacteria itself and its products may cause inflammatory responses that release 
pro-carcinogenic cytokines, pro-tumorigenic cytokines, or carcinogenic 
metabolites, or the enzymatic activity of the bacteria causing the creation of pro-
carcinogenic byproducts that can increase the genesis of colorectal cancer, see 
Figure 7 (G. Y. Chen, Shaw, Redondo, & Núñez, 2008; Zhang & Ghosh, 2001; 
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Zhu et al., 2013). Therefore, the gut microbiome may induce CRC through 
causing chronic inflammation and creating DNA damaging metabolites and/or 
carcinogens (Hope, Hold, Kain, & El-Omar, 2005). It has also been suggested 
that there may be specific ‘super-bad’ bacteria that both activates certain immune 
pathways and creates carcinogenic byproducts such as hydrogen peroxide, a 
potent DNA damaging reactive oxygen species, which may contribute 
significantly to CRC development (Sears & Pardoll, 2011). Two bacterial 
enzymes, β-glucuronidase and 7α-dehydroxylase, may also contribute to CRC 
risk, as well as nitrate reductase activity (de Kok & van Maanen, 2000; Deschner, 
Cohen, & Raicht, 1981; Gill & Rowland, 2002; Gråsten et al., 2000; D.-H. Kim & 
Jin, 2001; Lee, Kim, Yim, & Joo, 2004; Reddy, Mangat, Weisburger, & Wynder, 
1977). 
 
 
 
 
 22 
 
 
Figure 7. Proposed Methods That Microbiota May Cause Cancer 
Microbes interacting with pattern recognition receptors (PRRs) and toll like receptors (TLRs), 
which are part of the innate immune system, signal pro-inflammatory signaling pathways that may 
increase the risk of developing CRC. The enzymatic activity of the microbiome may also create 
carcinogenic byproducts from pre-carcinogenic molecules (Zhu et al., 2013). 
It is evident that the human gut microbiome influences the development of 
colorectal cancer. Colon cancer’s significance warrants investigation into factors 
that may ameliorate its mortality or reduce the incidence. There have been a 
multitude of animal studies that have shown specific bacteria cause CRC. It has 
been shown that dysbiosis exists in patients with CRC. While it may be specific 
bacteria that influence CRC, or only the ratio or proportion that these bacteria are 
present in the gut, it is imperative that we investigate whether changing the 
microbiome can help the prognosis of CRC or prevent it all together. 
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1.5.3 Obesity and Microbiome 
According to the World Health Organization, the rate of obesity has nearly 
doubled worldwide since 1980 (World Health Organization, 2013). Overweight 
adults, 20 years of age or older surpassed 1.4 billion in 2008, with 500 million of 
those individuals categorized as obese (World Health Organization, 2013). Sadly, 
over 40 million children younger than 6 were overweight in 2011 (World Health 
Organization, 2013). The United States leads the world, with two-thirds of its 
adult population being overweight, half of whom are considered obese (World 
Health Organization, 2013). This is an alarming trend that has an enormous 
impact on the public health of a nation (World Health Organization, 2013). 
 Obesity, now officially recognized as a disease by the American Medical 
Association (AMA), entails a host of comorbid diseases, including a fatty liver, 
hypertension, hyperlipidemia, insulin resistance and the buildup of surplus intra-
abdominal adipose tissue, in conjunction with a chronic low-grade whole body 
inflammation, which is the main contributing factor to many types of chronic 
diseases (Poirier et al., 2006; Shoelson, Herrero, & Naaz, 2007). Being 
overweight or obese as an adult has significant comorbidity with a multitude of 
diseases, such as cardiovascular diseases, hypertension, diabetes, osteoarthritis 
and some types of cancer (endometrial, breast and colon) (Poirier et al., 2006; 
Shoelson et al., 2007; World Health Organization, 2013). In children, obesity is 
linked to difficulty breathing, vulnerability to fracture, hypertension, psychological 
stress, and continues into adulthood (Poirier et al., 2006; Shoelson et al., 2007). 
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Globally, being overweight or obese is the fifth leading cause of death, with an 
annual 2.8 million adult deaths (World Health Organization, 2013). Clearly 
obesity is a force to be reckoned with; many scientists are investigating why 
there has been such a recent explosion in obesity (Kverka & Tlaskalova-
Hogenova, 2013; Riley, Raphael, & Faerstein, 2013; F. Tsai & Coyle, 2009; Żak-
Gołąb, Olszanecka-Glinianowicz, Kocełak, & Chudek, 2014). Recently, focus has 
turned to the gut microbiome and its possible role in obesity (Frazier, DiBaise, & 
McClain, 2011; F. Tsai & Coyle, 2009). 
 Using mice, several researchers have demonstrated some possible 
effects of altering the intestinal microbiome on obesity outcomes (Bäckhed et al., 
2004; Bäckhed, Manchester, Semenkovich, & Gordon, 2007; Turnbaugh et al., 
2006; Turnbaugh, Bäckhed, Fulton, & Gordon, 2008). Compared to germ free 
mice, conventionally raised mice exhibited an increase of 40% in body fat content 
and 47% higher gonadal fat, despite eating less (Bäckhed et al., 2004).  
To further demonstrate that this was due to the activity of the microbiome, 
the microbiota of the conventional mice were transplanted to the previously germ 
free mice (Bäckhed et al., 2004). The previously germ free mice then 
experienced an 57% increase in total body fat, a 61% increase in gonadal fat, 
and developed insulin resistance two weeks post-transplant (Bäckhed et al., 
2004). All of this occurred with the previously germ free mice continuing to eat 
the same amount of food and continuing similar exercise (Bäckhed et al., 2004). 
The conventionalized mice showed increased monosaccharide uptake compared 
 25 
 
to their germ free counterparts, as well as increased signaling to the liver to 
generate triglycerides (Bäckhed et al., 2004). This suggests that the transferred 
microbiota not only helps intestinal epithelial cells absorb nutrients, but can also 
change host metabolism (Bäckhed et al., 2004). Furthermore, these microbiota 
also suppressed the intestine from producing circulating lipoprotein lipase 
inhibitor, which increased deposition of triglycerides in adipocytes as well as 
heart muscle (Bäckhed et al., 2004). These experimental data help display that 
the microbiome can have profound impacts on the host metabolism and 
metabolic profile. In fact, it has been shown that germ free mice fed a diet that 
mimics much of the western world, i.e. high in fat and sugar, failed to develop 
obesity or insulin resistance (Bäckhed et al., 2004). This continues to provide 
evidence that the microbiome is crucial to the development of obesity.  
Furthermore, using a leptin deficient mouse model for obesity, Turnbaugh 
et al. (2006) demonstrated similar results when transferring microbiota from the 
obese mice’s ceca to germ free mice. Recipients of the obese mice’s cecal 
contents gained 74% more body fat two weeks post transplantation than their 
counterparts who received lean mice cecal contents, despite eating less than 
pre-transplantation (Turnbaugh et al., 2006). Since the transplant recipients’ 
cecal contents continued to mirror their donors post transplantation, this shows 
that obesity can be transferred through microbiota (Turnbaugh et al., 2006). 
 When investigating the actual makeup of the mice cecal contents, it was 
discovered in multiple studies that the phylum Firmicutes were enriched and 
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Bacteroidetes were concordantly reduced in obese mice when compared to lean 
mice (Ley et al., 2005; Turnbaugh et al., 2006). Furthermore, when investigating 
the effect of diet on mice, it was found that the respective increase/decrease in 
Firmicutes/Bacteroidetes was primarily due to the type of diet eaten, independent 
of their obese state (Hildebrandt et al., 2009). This helps explain that the disease 
state is not solely responsible for these changes in the microbiome, but rather the 
microbiome is independent of this disease state (Hildebrandt et al., 2009).  
 When investigating humans, the trend that obese people have enriched 
levels of Firmicutes with a corresponding drop in Bacteroidetes is more 
controversial, with multiple studies conflicting or failing to confirm this observation 
(Collado, Isolauri, Laitinen, & Salminen, 2008; Cotillard et al., 2013; Duncan et 
al., 2008; Kalliomäki, Collado, Salminen, & Isolauri, 2008; Le Chatelier et al., 
2013; Ley, Turnbaugh, Klein, & Gordon, 2006; Santacruz et al., 2009; Schwiertz 
et al., 2010). However, the contradicting studies by Duncan et al. (2008), 
Kalliomäki et al. (2008), and Santacruz et al. (2009), had varying methodologies 
with only Schwiertz et al. (2010) making the direct pre-intervention comparisons 
between obese and lean individuals’ microbiomes. Schwiertz et al. (2010) also 
summed Bacteroidetes and Prevotella genera to obtain their total for the phylum 
Bacteroidetes, potentially leaving out bacteria belonging to other genera that 
belong to the Bacteroidetes phylum; thus, conclusion that Bacteriodetes and 
Firmicutes are not related to obesity may not be entirely accurate (Million et al., 
2012). 
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Despite the controversy over the role that the ratio of Firmicutes to 
Bacteroidetes plays in obesity, there have been more specific observations on 
which species of bacteria may be implicated (Million et al., 2012; Schwiertz et al., 
2010).  A decrease in Methanobrevibacter was associated with obesity (Le 
Chatelier et al., 2013; Million et al., 2012; Schwiertz et al., 2010). In addition 
Bifidobacterium was negatively correlated with BMI in obese subjects (Schwiertz 
et al., 2010). Lactobacillus paracasei and Bifidobacterium animalis was 
associated with leanness (Million et al., 2012). However, overall increased 
numbers of the Lactobacillus genus, notably L. reuteri, was associated with 
obesity (Million et al., 2012).  
 In contrast to trying to classify what bacteria exist in the gut microbiome of 
obese individuals, some researchers have investigated the metagenomics 
through WGS (Cotillard et al., 2013; Le Chatelier et al., 2013; Schwiertz et al., 
2010; Turnbaugh et al., 2009). It was found that phosphotransferase systems, 
systems involved in microbe carbohydrate usage, were increased in obese 
individuals (Turnbaugh et al., 2009). Obese individuals also had increased 
Actinobacteria genes whereas increased Bacteroidetes genes were associated 
with lean individuals (Turnbaugh et al., 2009). While methods have varied there 
is clearly a difference in the microbiomes between those with obesity and not. 
 Some researchers have linked obesity and comorbid diseases with low 
microbial genetic diversity (Cotillard et al., 2013; Le Chatelier et al., 2013). 
Individuals with low microbial genetic diversity had increased gene density for 
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metabolic pathways suggesting increased capability to neutralize reactive oxygen 
species as well as increased capability to produce procarcinogens (Le Chatelier 
et al., 2013). In addition, there were noted decreases in butyrate producing 
bacteria, potentially increased mucus breakdown due to decreases in 
Akkermansia to R.torque/gnavus ratio, potential decreases in hydrogen and 
methane production with increases in hydrogen sulfide, increases in 
Campylobacter and Shigella, and increased ability to handle oxidative stress 
using peroxidase (Le Chatelier et al., 2013). These data suggests that low 
genetic diversity microbiomes are pro inflammatory (Le Chatelier et al., 2013). 
Indeed, obese individuals with low microbial gene diversity had higher BMIs, less 
insulin sensitivity, higher fasting serum triglycerides, and higher LDL cholesterol 
and inflammation than their high gene diversity microbiome counterparts 
(Cotillard et al., 2013). Pro inflammatory states may play a role in metabolic 
endotoxemia, which may be significant in determining future complications and a 
poor prognosis of obesity (Frazier et al., 2011). With yet another way to 
investigate the gut microbiome of humans it may be hard to decipher what is 
important and what is not, with future studies it may be helpful to do both 16S 
rRNA, WGS and gene diversity measurements so studies can be analyzed 
across the board.  
 Yet another investigation into obesity and the human gut microbiome 
revealed that irrespective of microbial makeup, it was really increases in short 
chain fatty acid concentration (SCFA) that predicted obesity in humans 
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(Schwiertz et al., 2010). Obese volunteers had 20% increases in SCFA 
concentration in stool samples than their lean counterparts, with the greatest 
increase in propionate (Schwiertz et al., 2010). SCFA’s are a primary fuel for 
epithelial cells of the colon and can be used in other host metabolic processes for 
energy (Schwiertz et al., 2010). Stool SCFA concentration may play a role in 
controlling host metabolism and is the subject of future studies (Puertollano, 
Kolida, & Yaqoob, 2014). However, Schwiertz et al. (2010) did not take into 
account diet, exercise, and other lifestyle habits which may be correlated with 
SCFA production and obesity. So while SCFA concentration in stool correlates 
with obesity, causative effects have yet to be determined (Million et al., 2012). 
 Distal gut microbiota are responsible for utilizing calories from food that 
human enzymes alone cannot process, storing those calories into host fat for 
later use, as well as providing necessary nutrients for microbial self-preservation 
and growth (Frazier et al., 2011). The hypothesized mechanisms by which the 
microbiota may exert their influence on obesity include: inhibition of circulating 
lipoprotein lipase inhibitor, increased gut permeability leading to increased 
nutrient absorption, increased nutrient breakdown and concordant availability to 
the host, and host immune system interactions may all be potential mechanisms 
that influence the development and course of obesity (Bäckhed et al., 2007; 
Bashir, Louie, Shi, & Nagler-Anderson, 2004; Frazier et al., 2011; Ley et al., 
2006; Million et al., 2012; Schwiertz et al., 2010).  
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 Obesity is a worldwide problem (World Health Organization, 2013). The 
microbiome has been implicated in the genesis of obesity and potentially poses a 
good venue for therapeutic interventions (Fukuda & Ohno, 2014). With this in 
mind it is imperative that we explore possible therapeutic strategies while 
keeping patient safety in mind. 
SPECIFIC AIMS 
It is clearly evident that the human microbiome is strongly implicated in a 
variety of human diseases. While there have been multiple studies on ways to 
potentially alter the intestinal microbiome (Butel, 2013; Fallucca, Porrata, 
Fallucca, & Pianesi, 2014; K.-A. Kim, Gu, Lee, Joh, & Kim, 2012; Matuchansky, 
2014; F. Tsai & Coyle, 2009; Xu et al., 2014), this study aims to address the 
possible use of fecal microbiota transplants to alter the human intestinal 
microbiome in order to alleviate or cure diseases, while also assessing cost, 
feasibility, and safety. 
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PUBLISHED STUDIES 
2.0 What is a fecal microbiota transplant? 
 A fecal microbiota transplant (FMT) has also been known as fecal 
bacteriotherapy, fecal transplantation, transfaunation and human probiotic 
transplantation (Bakken et al., 2011). The concept behind FMT is that bacterial 
dysbiosis exists in the patient, usually due to some type of antibiotic insult, which 
leads to pathogenesis of certain disease states, notably C. difficile (Bakken et al., 
2011). By taking microbiota from a healthy donor and transplanting it into the 
recipient, the healthy flora can replace the diseased dysbiotic state (Bakken et 
al., 2011). Recipient preparation usually includes an abbreviated course of 
antibiotics followed by a colonoscopy flush (Bakken et al., 2011). Donor stool is 
usually collected fresh, blended into a suspension with saline, milk, or water, and 
then infused into the patient through nasogastric/nasoduodenal tubes, 
colonoscope, or using a retention enema (Bakken, 2009). 
2.1 Fecal microbiota transplants in Clostridium difficile infection (CDI) 
Two recent publications, a systematic-review of FMT and an overview of 
FMT for practitioners, provide an introduction to the use of FMT to treat CDI 
(Brandt & Aroniadis, 2013; Cammarota, Ianiro, & Gasbarrini, 2014). These 
sources were combined with searches on PubMed and Web of Science to look 
for any publications regarding FMT treating CDI with the last search being 
3/March/2014. Four new hits were added to Table 2 to describe the current 
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summary of research done on FMT and CDI. There were 41 studies that directly 
described the use of FMT to treat CDI, with 40 being case studies and only 1 
being a randomized controlled trial (Bowden, Mansberger, & Lykins, 1981; Brace, 
Gloor, Ropeleski, Allen-Vercoe, & Petrof, 2014; Brandt et al., 2012; Collins, 1960; 
Eiseman, Silen, Bascom, & Kauvar, 1958; Fenton, Stephenson, & Weder, 1974; 
Fløtterød & Hopen, 1991; Friedman-Moraco, Mehta, Lyon, & Kraft, 2014; 
Gallegos-Orozco, Paskvan-Gawryletz, Gurudu, & Orenstein, 2012; Garborg, 
Waagsbø, Stallemo, Matre, & Sundøy, 2010; Gustafsson, Berstad, Lund-
Tønnesen, Midtvedt, & Norin, 1999; Hamilton, Weingarden, Sadowsky, & 
Khoruts, 2012; Härkönen, 1996; Hellemans, Naegels, & Holvoet, 2009; Jorup-
Rönström et al., 2012; S. A. Kahn, Young, & Rubin, 2012; Kassam, Hundal, 
Marshall, & Lee, 2012; Khoruts, Dicksved, Jansson, & Sadowsky, 2010; Kleger 
et al., 2013; Lund-Tønnesen, Berstad, Schreiner, & Midtvedt, 1998; 
MacConnachie, Fox, Kennedy, & Seaton, 2009; Mattila et al., 2012; Nagy, 
Várvölgyi, & Paragh, 2012; Neemann et al., 2012; Nieuwdorp et al., 2008; 
Paterson, DL, 1994; Persky & Brandt, 2000; Polák et al., 2011; Quera, Espinoza, 
Estay, & Rivera, 2014; Rohlke, Surawicz, & Stollman, 2010; Rubin, Gessert, Aas, 
& Bakken, 2013; Russell, Kaplan, Ferraro, & Michelow, 2010; Schwan, Sjölin, 
Trottestam, & Aronsson, 1983; Shahinas et al., 2012; Silverman, Davis, & Pillai, 
2010; Trubiano et al., 2013; Tvede & Rask-Madsen, 1989; van Nood et al., 2013; 
Yoon & Brandt, 2010; You, Franzos, & Holman, 2008).   
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2.2 Analyzing the fecal microbiota transplant studies 
These studies were analyzed for numbers of patients with CDI treated with 
FMT, the average age and range of patients, whether or not the patients were 
experiencing recurrent bouts of CDI or if this was their first episode, the method 
used to deliver the FMT, the number of patients whose diarrhea resolved post 
FMT, the number that tested negative for C. Difficile toxin post FMT, whether or 
not the patients had received previous therapy (usually oral antibiotics) prior to 
FMT, and whether or not any adverse events were reported. These data were 
put into Table 1.  
The average patient age was 64 years old, with an age range of 1 to 94 
years old. There were studies that involved children (S. A. Kahn et al., 2012; 
Russell et al., 2010). The 41 studies spanned the globe but reflected an 
emphasis on Western countries, with the most number coming from the USA at 
15 (Table 1). A total of 569 patients have been treated with FMT in the selected 
literature. 
2.3 Methods of FMT used 
The method of infusing the FMT was varied between studies (Brandt & 
Aroniadis, 2013; Cammarota et al., 2014). 17 studies utilized colonoscopies, 13 
used enemas, 11 did some variety of naso-gastric/duodenal or endoscopy 
procedure, with only 2 using gastrostomy lines (Table 1). Colonoscopy was 
preferred by some for the ability to visualize the entire colon for other diseases, 
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as well as being able to access the entire colon for transferring the FMT 
(Cammarota et al., 2014). However, distal enema and nasogastric (NG) tubes 
were considered cheaper and less invasive than colonoscopy procedures 
(Bakken, 2009; Brandt & Aroniadis, 2013; Kassam et al., 2012). There has been 
no study that has compared the efficacy of using different routes of inoculation.  
Hamilton et al. (2012) were the only researchers who used frozen donor 
samples, with every other study using fresh stool samples. Polyethylene glycol 
bowel preparation was used in a minimum of three studies, including the 
randomized controlled study (van Nood et al., 2013). Observationally, there was 
a strong trend where patients would stop antibiotic treatment in preparation for 
their FMT (Bakken, 2009; Brandt & Aroniadis, 2013; Cammarota et al., 2014).  
There was no consensus amount of donor sample and infusion volume 
used between the studies, but Bakken (2009) does suggest quantities at 25-30 g 
of stool for upper gastrointestinal tract infusions and 200-300g for lower 
gastrointestinal infusions. 
 35 
 
Table 1: Results from reviewing data on FMT related studies. 
Nr is not reported, diarrhea resolved is the number of people cured by FMTs. Appended from 
(Cammarota et al., 2014). 
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Table 1 (continued): Results from reviewing data on FMT related studies. Appended from 
(Cammarota et al., 2014). 
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Table 1 (continued): Results from reviewing data on FMT related studies. Appended from 
(Cammarota et al., 2014). 
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2.4 FMT safety 
Most studies described their procedures for screening donors, often 
testing for communicable diseases such as human immunodeficiency virus, 
Hepatitis A, B, C, sexually transmitted diseases, as well as common stool 
parasites such as Cryptosporidium and Giardia (Brandt & Aroniadis, 2013; 
Cammarota et al., 2014). In addition, donors usually were required not to have 
any current known digestive problems or have taken antibiotics in previous 
months (Brandt & Aroniadis, 2013; Cammarota et al., 2014). With such interest in 
FMT, a guide has been published on how FMT’s should be conducted, including 
minimum safety considerations that should be in place (Bakken, 2009). 
Common side effects reported were diarrhea, cramping, fatigue and 
belching (Brandt et al., 2012; van Nood et al., 2013). These symptoms often went 
away quickly, from a couple of hours to days (Brandt et al., 2012; van Nood et 
al., 2013). These symptoms were well tolerated (Brandt et al., 2012; van Nood et 
al., 2013). 
There has only been one serious adverse reaction to an FMT in published 
papers (Quera et al., 2014). A 61 year old patient with recurrent severe CDI, 
Crohn’s disease, and acute diverticulitis was evaluated for FMT after hospital 
admission due to his CDI relapse (Quera et al., 2014). After safety screening and 
following pre FMT protocol, the patient received a FMT, but within 24 hours 
developed a high grade fever and bacteremia (Quera et al., 2014). The patient 
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was treated with a course of antibiotics that cured his bacteremia, and 6 months 
post FMT he is C. difficile free when measured by PCR (Quera et al., 2014). 
In the only published long term FMT follow up study, there were four 
cases of patients reporting new adverse medical conditions after receiving a FMT 
(Brandt et al., 2012). These new conditions were unexplained and included 
peripheral neuropathy, Sjogren’s disease, idiopathic thrombocytopenic purpura, 
and rheumatoid arthritis (Brandt et al., 2012). In addition two patients reported 
improvement in their allergic sinusitis and arthritis post FMT (Brandt et al., 2012). 
2.5 Does fecal microbiota transplantation work in patients with CDI? 
 Almost all patients that underwent FMT were those who suffered from 
recurrent bouts of hard to treat CDI (Table 1). These patients are the hardest to 
treat with conventional therapeutic strategies, as each bout of CDI decreases the 
chances that a course of antibiotics will work (Dynamed, 2013). Antibiotic 
effectiveness drops to a 30% success rate in patients with recurrent CDI (Brandt 
& Aroniadis, 2013; Cammarota et al., 2014; Dynamed, 2013). However, the use 
of FMT has an average success rate of around 88% (Table 2). 
Table 2: FMT success rates per infusion method used.  
Resolution of CDI was categorized by absence of diarrhea post FMT. 
Infusion Method 
Number of 
Treated Patients 
CDI 
Resolved Percent success 
Colonoscopy 249 218 88% 
Naso-
gastric/duodenal/jejunal 
Tube 
230 199 87% 
Enema 89 80 90% 
All Methods 569 498 88% 
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Observationally, there seems to be no difference among success rates 
between the intervention groups. The only randomized controlled trial comparing 
the efficacy of FMT to vancomycin was stopped short at its interim analysis 
because the FMT was so effective it would have been unethical to continue 
treating patients with vancomycin (van Nood et al., 2013). FMT was seen as 
having a 94% overall cure rate compared to 31% for vancomycin (van Nood et 
al., 2013) In the long term follow up study, Brandt et al. (2012) reported that 97% 
patients were willing to undergo FMT again if they experienced another bout of 
CDI. Furthermore, 53% stated they would want FMT as a first line treatment 
instead of antibiotics (Brandt et al., 2012). This suggests that not only is FMT 
effective, but also very well tolerated among patients. 
2.6 FMT in patients with ulcerative colitis 
 While CDI is the basis for the bulk of FMT studies, there have been 
investigations into whether FMT can affect the outcome of ulcerative colitis, an 
inflammatory bowel disease (Borody, Warren, Leis, Surace, & Ashman, 2003). 
Six subjects with ulcerative colitis aged 25-53, who had suffered from ulcerative 
colitis less than 5 years with consistent recurrent symptoms, underwent FMT 
(Borody et al., 2003). Donors were healthy adults screened for most common 
pathogens and communicable diseases (Borody et al., 2003). Polyethylene 
glycol and oral antibiotics were used to prepare subjects before undergoing FMT 
by retention enema (Borody et al., 2003). The process was repeated for 5 days 
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straight, but by 1 week post FMT some patients were experiencing fewer 
symptoms of their ulcerative colitis (Borody et al., 2003). Four months post FMT, 
all six patients were free from all ulcerative colitis symptoms (Borody et al., 
2003). During follow up 1-13 years after FMT there is no evidence of the treated 
patients having ulcerative colitis (Borody et al., 2003).  
2.7 FMT in patients with metabolic syndrome 
 Metabolic syndrome is a disease of discordant energy utilization and 
storage (“Metabolic syndrome,” 2014). Diagnosis criteria requires both central 
obesity (waist circumference greater than 94 cm for European men) and at least 
two of the following: high serum triglycerides, low levels of high density 
lipoprotein cholesterol, high blood pressure, and high blood glucose levels (R. 
Kahn, Buse, Ferrannini, & Stern, 2005). 
 In a randomized controlled study, nine men with metabolic syndrome were 
selected to receive FMT from either lean donors or autologous donations (Vrieze 
et al., 2012). Subjects were blinded to which sample they were receiving (Vrieze 
et al., 2012). Insulin sensitivity was measured pre and 6 weeks post FMT using a 
“hyperinsulinemic euglycemic clamp”, the gold standard when measuring insulin 
sensitivity (Vrieze et al., 2012). Additionally, fecal samples and duodenal 
samples were taken pre and post FMT to reflect possible changes in the 
microbiota located in large intestine and small intestine locations (Vrieze et al., 
2012).  
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 Six weeks post FMT, there was a statistically significant improvement in 
insulin sensitivity in lean donor recipients when compared to the autologous 
recipients (Vrieze et al., 2012). There was no difference in resting energy 
expenditure, diet composition, or hormonal profile to explain this cause (Vrieze et 
al., 2012). When analyzing the diversity of the microbiota of participants post 
FMT, it was discovered that the gut microbial diversity increased drastically after 
receiving lean donor sample; however, there was no statistically difference in 
autologous sample recipients (Vrieze et al., 2012).  
DISCUSSION 
It is clear that fecal microbiota transplants are extremely effective, 
relatively cheap to do, and well tolerated by patients. After getting over the 
hurdles of having a donor screened and then provide the patient with a fresh 
sample, all a practitioner needs is some saline, a nasogastric tube with syringe, a 
strainer and a dedicated blender (Bakken, 2009). While it may be a little 
uncomfortable for the patient undergoing the colonoscopy cleanse before FMT, 
the resulting procedure is quick and the effects are almost immediate (Anderson, 
Edney, & Whelan, 2012; Bakken, 2009; Brandt & Aroniadis, 2013; Neemann et 
al., 2012). When comparing the alternative of having recurrent bouts of horrible 
diarrhea that may land a patient in the hospital versus one thirty minute 
procedure, it is clear that FMT should be at the forefront of treating CDI, and not 
a last resort. 
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However, caution must be exercised in interpreting the available data. To 
date, there has yet to be one well designed experiment that investigates what 
types of FMT are better others. There have been no systematic evaluations on 
whether colonoscopy, naso-gastro/duodenal/jejunal tubes, or retention enemas 
are any better than the other. In addition, there is no research on exactly how 
much fecal bacteria need to be transplanted to be effective, or whether a pre 
FMT colon cleanse is necessary, or beneficial. Furthermore, there was only one 
study that investigated the use of frozen donor samples in FMT, and it showed to 
be efficacious (Hamilton et al., 2012). It would be helpful for practitioners and 
donors alike, if screened healthy samples could be frozen and prepared ahead of 
time, so patients were not at the mercy of a donor’s digestive timetable. If 
preparing samples ahead of time is feasible, then effort should be made to find a 
single donor or a set of specific donors to potentially help control the variability in 
donor samples to allow conclusions on the effectiveness of specific donor FMTs.  
Furthermore, with the microbiome’s recent implication in a host of possible 
diseases such as diabetes, obesity, colon cancer, rheumatoid arthritis and 
autoimmunity, ulcerative colitis, metabolic syndrome, multiple sclerosis, 
fibromyalgia, and allergies, it should be imperative that practitioners do not rush 
into treating one disease while causing another (Abrahamsson et al., 2012, 2013; 
Brace et al., 2014; Butel, 2013; Fukuda & Ohno, 2014; Kverka & Tlaskalova-
Hogenova, 2013; Vrieze et al., 2012). It is extremely important that science and 
practice stay mindful of these possible connections and be extra vigilant in the 
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screening process of donors. One only needs to remember the large amounts of 
hemophiliacs infected with Human Immunodeficiency Virus during blood 
transfusions in the late 1970’s simply because the medical community did not 
know any better (“Contaminated haemophilia blood products,” 2014). It should 
also be of note that many of the diseases that are possibly linked to the 
microbiome are insidious in nature, with no clear cause or methodology (Brandt 
& Aroniadis, 2013; Hornig, 2013). In essence, while FMTs have few to no 
recorded adverse events in published literature to date, this does not mean there 
won’t be repercussions down the road (Brandt & Aroniadis, 2013; Cammarota et 
al., 2014; Quera et al., 2014). As the previous United States Secretary of 
Defense, Donald Rumsfeld, once said “… as we know, there are known knowns; 
there are things we know that we know. There are known unknowns; that is to 
say, there are things that we now know we don't know. But there are also 
unknown unknowns – there are things we do not know we don't know” (“There 
are known knowns,” 2014). 
This warning is also aimed towards antibiotics. Now that science knows 
the microbiome is not static and can change with differing insults, it is imperative 
that practitioners limit our use of antibiotics to true medical emergencies (Huse, 
Ye, Zhou, & Fodor, 2012; Shahinas et al., 2012; Theriot et al., 2014). Since 
bacteria are clearly big players in the host’s wellbeing, antibiotic genocide of its 
commensal organisms should not be taken lightly. Similar to the need of 
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investigating FMT further, studies involving antibiotics should look at the long 
term effects of Western cultures exuberant use of them (“Antimicrobial,” 2014).  
However, this is not to say that science should stop because it’s scared. 
With the multitude of disease states that have been associated with the human 
digestive microbiome, such as ulcerative colitis, irritable bowel disease and 
syndrome, C. difficile infections, Crohns disease, and esophageal cancer as well 
as the possible interplay with the immune system, which implicates the 
microbiome in rheumatoid arthritis, allergies, Parkinson’s disease, multiple 
sclerosis and chronic inflammation, we now have a new therapeutic approach, 
FMT, that is proven to change the microbiota of a recipient (Abrahamsson et al., 
2013; Borody et al., 2003; Brandt & Aroniadis, 2013; Critchfield, van Hemert, 
Ash, Mulder, & Ashwood, 2011; Crouzet et al., 2013; Kverka & Tlaskalova-
Hogenova, 2013; Shahinas et al., 2012). We now have more knowledge than we 
ever did, thanks to the scientists working on the Human Microbiome Project and 
metaHIT  
CONCLUSION 
 The human microbiome is an exciting new frontier that has the potential to 
open a completely new avenue of treatment and therapeutic targets for treating a 
wide range of potentially related diseases. The strides scientists have made in 
mapping out the genomes of the microbiota has been significant. With this new 
data, a range of disease states are being implicated with human microbiota 
dysbiosis. Fecal microbiota transplants are an easy, cheap, safe, and powerful 
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tool in altering a recipient’s microbiome. While research needs to be done to 
standardize and solidify FMT’s and prove its long term safety in treating CDI, the 
ability to use FMT to alter both CDI and other disease courses is an exciting 
possibility. 
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